# US 2019/0376067 A1 · Compositions, methods and uses for multiplexed trackable genomically-engineered polypeptides

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0376067 A1
- Document ID: US20190376067A1
- Status: Published application
- Kind: A1
- Application number: 16/485,333
- Filed: 2018-02-13
- Published: 2019-12-12
- Earliest claimed: 2017-02-13
- Assignees: The Regents of the University of Colorado, a body corporate
- Applicants: The Regents of the University of Colorado, a Body Corporate
- Inventors: Ryan T. Gill; William Grau
- Web page: https://patentgrep.com/patent/US20190376067A1

## CPC

- C12N 15/52: Genes encoding for enzymes or proenzymes
- C12N 15/1072: {Differential gene expression library synthesis, e.g. subtracted libraries, differential screening}
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- C12N 15/70: Vectors or expression systems specially adapted for E. coli
- C40B 40/08: Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
- C40B 50/10: involving encoding steps
- G16B 25/00: ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- C07K 2319/00: Fusion polypeptide
- C12N 9/10: Transferases (2.) (ribonucleases C12N9/22)
- C12N 9/16: acting on ester bonds (3.1)
- C12N 9/90: Isomerases (5.)
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C40B: COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES (in silico combinatorial libraries of nucleic acids, proteins or peptides G16B35/00; in silico combinatorial chemistry G16C20/60)
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Embodiments herein concern compositions, methods, systems and uses for in vivo selection of optimum target proteins of use in designing genomically-engineered cells or organisms. Some embodiments relate to compositions and methods for generating constructs mimicking benefits of megasynthases in a non-natural organism or cell of use in systems and methods disclosed herein. Yet other embodiments relate to compositions and methods for generating agents using constructs disclosed herein of use in treating genetically-linked conditions.

## Claims

### Claim 1

A construct, comprising:
a non-naturally occurring polypeptide having a formula represented by (X—B)n—Z, wherein:
X comprises at least one polypeptide encoding at least one domain of a first target protein;
Z comprises at least one polypeptide encoding at least one domain of a second target protein;
B comprises a polypeptide for linking X and/or Z; and
n is a number from 1 to 100;
wherein the non-naturally occurring polypeptide having (X—B)n—Z as a formula is capable of synthesizing a secondary metabolite in a cell or organism.

### Claim 2 (depends on 1)

The construct according to claim 1, wherein the at least one domain comprises at least one catalytic of the first target protein or the second target protein.

### Claim 3

The construct according to any one of the preceding claims, wherein the first target protein comprises a megasynthase, a polyketide synthase, a non-ribosomal peptide synthase, and/or hybrid thereof.

### Claim 4

The construct according to any one of the preceding claims, wherein the second target protein comprises a megasynthase, a polyketide synthase, a non-ribosomal peptide synthase, and/or hybrid thereof.

### Claim 5

The construct according to any one of the preceding claims, wherein the construct comprises a modular megasynthase.

### Claim 6

The construct according to any one of the preceding claims, wherein the first target protein and the second target protein are the same protein.

### Claim 7

The construct according to any one of the preceding claims, wherein X comprises a polypeptide sequence of at least one domain selected from the group consisting of: Acyltransferase (AT), Acyl Carrier Protein (ACP), Keto-Synthase (KS), Ketoreductase (KR), Dehydratase (DH), Enoylreductase (ER), Methyltransferase (MT), Sulfhydrolase (SH), and Thioesterase (TE).

### Claim 8

The construct according to any one of the preceding claims, wherein Z comprises a polypeptide sequence of at least one domain selected from the group consisting of: Acyltransferase (AT), Acyl Carrier Protein (ACP), Keto-Synthase (KS), Ketoreductase (KR), Dehydratase (DH), Enoylreductase (ER), Methyltransferase (MT), Sulfhydrolase (SH), and Thioesterase (TE).

### Claim 9

The construct according to any one of the preceding claims, wherein B comprises a polypeptide sequence selected from the group consisting of: Acyl Carrier Protein-Condensation Domain linkers (ACP Condensation), Acyl Carrier Protein-Heterocyclization Domain linkers (ACP Heterocyclization), Acyl Carrier Protein-Ketosynthase Domain linkers (AC-PKS), Acyl Carrier Protein-Thioesterase Domain linkers (ACP-TE), Adenylation Domain-Peptide Carrier Protein linkers (A-PCP), Acyltransferase Domain-Acyl Carrier Protein linkers (AT-ACP), Acyltransferase Domain-Dehydratase Domain linkers (AT-DH), Acyltransferase Domain-Ketoreductase Domain linkers (AT-KR), Condensation Domain-Adenylation Domain linkers (Condensation A), Dehydratase Domain-Enoylreductase Domain linkers (DH-ER), Dehydratase Domain-Ketoreductase Domain linkers (DH-KR), Dual Condensation/Epimerization Domain-Adenylation Domain linkers (Dual Condensation A), Enoylreductase Domain-Ketoreductase Domain linkers (ER-KR), Heterocyclization Domain-Adenylation Domain linkers (Heterocyclization A), (Both Acyl and Peptide) Carrier Protein-Condensation Domain linkers (Joint AC-PC), Ketoreducatse Domain-Acyl Carrier Protein linkers (KR-ACP), and Ketosynthase Domain-Acyltransferase Domain linkers (KS-AT).

### Claim 10

The construct according to any one of the preceding claims, wherein the secondary metabolite comprises:

### Claim 11

The construct according to any one of the preceding claims, wherein the secondary metabolite is selected from the group consisting of: delta-hexalactone, Rapanycin, Actinorhodin, Erythromycin A, 6-Methylsalicyclic acid, Aflatoxin B1, Rifamycin S, Lovastatin, Amphotericin B, and Monensin A.

### Claim 12

The construct according to any one of the preceding claims, wherein the first target protein or the second target protein is a prokaryotic protein or a eukaryotic protein.

### Claim 13

The construct according to any one of the preceding claims, the construct having the formula (X—B)n—Z is a polypeptide having at least 95 percent identity to at least one polypeptide selected from the group consisting of the polypeptides represented by at least one of SEQ ID NOs: 33-64, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135, 137, 139, 141, 143.

### Claim 14

The construct according to any one of the preceding claims, wherein B comprises a polypeptide sequence represented by at least one of SEQ ID NOs: 70-71, 73-74, 76-79, 81-82, 84-86, 88-91, 93-96, 98-99, 101-107.

### Claim 15

A non-naturally occurring polynucleotide comprising a polynucleotide encoding the construct of any one of the preceding claims.

### Claim 16 (depends on 15)

The polynucleotide according to any one of claim 15, wherein the polynucleotide can be compiled together with other polynucleotides to make a library of one or more target proteins, secondary metabolites or a trait.

### Claim 17 (depends on 15, 16)

The polynucleotide according to claim 15 or 16, wherein the polynucleotide is a polynucleotide having at least 95 percent identity to at least one polynucleotide selected from the group consisting of the polynucleotides represented by at least one of SEQ ID NOs: 1-32, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

A host for producing a construct according to any one of claims 1-14.

### Claim 19 (depends on 18)

The host according to claim 18, wherein the host comprises Escherichia coli.

### Claim 20 (depends on 18)

The host according to claim 18, wherein the construct produces a genetic modification to overcome a deleterious trait in a human gene where the human gene is homologous to an E. coli gene and wherein the deleterious trait is selectable.

### Claim 21

A method for generating a construct, comprising:
obtaining at least one polynucleotide sequence encoding at least one domain of a first target protein and at least one polynucleotide sequence encoding at least one domain of a second target protein;
determining a linker polynucleotide that is capable of encoding a protein linking the at least one domain of the first target protein and the at least one domain of the second target protein; and
generating a polypeptide construct having the at least one polypeptide sequence encoding the first target protein and at least one polypeptide sequence encoding the second target protein and a polypeptide sequence encoding the linker polypeptide.

### Claim 22 (depends on 21)

The method according to claim 21, wherein the step of determining the polynucleotide sequence encoding the linker polypeptide further comprising creating a gene cluster annotation of the target gene encoding the linker polypeptide.

### Claim 23 (depends on 21, 22)

The method according to any one of claims 21-22, further comprising converting the construct having the at least one polypeptide sequence and the linker sequence into at least one nucleotide sequence by using codon harmonization.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

A method for generating a biopharmaceutical agent, comprising:
introducing into cells a vector that encodes a construct according to any one of claims 1-14;
obtaining viable cells expressing the vector; and
isolating the biopharmaceutical agent from the viable cells.

### Claim 25 (depends on 24)

The method according to claim 24, further comprising: introducing a mutation into the cells, wherein the mutation causes a condition.

### Claim 26 (depends on 25)

The method according to claim 25, wherein the condition comprises a genetic disease.

### Claim 27 (depends on 26)

The method according to claim 26, wherein the genetic disease comprises a loss-of-function genetic disease or a gain-of-function genetic disease.

### Claim 28 (depends on 15, 16, 17)

A method for generating an in vivo construct library comprising generating the polynucleotides according to claims 15 to 17, wherein each polynucleotide represents one genetic variation in a target gene of a target protein and the construct library comprises all naturally-occurring and non-natural amino acid residue changes of the target protein.

### Claim 29

A method comprising:
assigning ranks pertaining to biological effects of genetic variations of a plurality of genes or genetic loci capable of coding for a target protein;
assigning ranks pertaining to the biological effect due to the genetic variations of the plurality of genes or genetic loci;
obtaining and analyzing one or more rank(s) of the genetic variations of the genes or genetic loci pertaining to a predetermined selection process;
obtaining one or more composite rank(s) based on the ranks of the biological effects as they pertain to the predetermined selection process and biological context rank; and
designing a genomically-engineered process, cell or organism based on the composite rank(s).

### Claim 30 (depends on 29)

The method according to claim 29, wherein the biological effect comprises a modulation of the target gene.

### Claim 31 (depends on 30)

The method according to claim 30, wherein the target gene comprises an enzyme and the modulation of the target gene comprises an increase in biological activity of the enzyme compared to a target gene not having the genetic variation.

### Claim 32 (depends on 29)

The method according to claim 29, where the assigning comprises measuring the effect of the genetic variation on a specific trait.

### Claim 33

A computer-readable medium having computer-readable instructions, which, when executed by a computer, cause the computer to carry out a method comprising:
receiving first gene(s) or genetic segment score representing a score of a biological effect or condition due to a genetic variation of a gene or gene segment of a target protein;
receiving at least a second gene(s) or genetic score representing a second score of another genetic variation of the target protein;
combining the scores; and
assigning a combined score related to one or more genetic variations in order to assess a value of the genetic variations related to a trait for the target protein.

### Claim 34 (depends on 33)

The computer-readable medium of claim 33, further comprising designing a genomically-engineered organism or cell based on the composite scores for two or more genes or genetic loci.

### Claim 35 (depends on 33)

The computer-readable medium of claim 33, wherein information related to more than one target gene can be received and assessed.

### Claim 36

A system comprising:
a component for assessing a score of a genetic variation of genes or genetic segments pertaining to a trait of one or more target proteins; and
a component for reporting the score of the genetic variation of genes or genetic segments pertaining to a trait of one or more target proteins; and
a component for compiling the scores of one or more target proteins.

### Claim 37 (depends on 36)

The system according to claim 36, wherein the genetic variation comprises a mutation, insertion, deletion or other genetic variation.

### Claim 38 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

A library comprising the constructs of claims 1-14 and/or the polynucleotides of claims 15-17.

### Claim 39 (depends on 38)

The library according to claim 38, wherein the library is a genomic library of a target microorganism.

### Claim 40 (depends on 38, 39)

The library according to any one of claims 38-39, wherein the constructs comprise all possible genetic variations together in a pool representing every mutated residue of the target protein.

### Claim 41 (depends on 15, 16, 17)

A method for engineering a polypeptide construct comprising:
obtaining the polynucleotide according any one of claims 15 to 17;
obtaining one or more oligonucleotide sequences, each containing regions of homology to one or more target gene(s), and regions of genetic variation towards one or more target gene(s);
using the one or more oligonucleotide sequences to generate amplified constructs comprising regions of homology suitable for homologous recombination within the polynucleotide; and
using the amplified constructs to create a library of mutant target genes within the polypeptide construct.

### Claim 42 (depends on 41)

The method according to claim 41, further comprising a traceable barcode positioned outside of the gene or the gene segment open reading frame in the amplified constructs, wherein the traceable barcode corresponds to or is quantitatively linked to a genetic variation of the gene or the gene segment.
